European Pharmaceutical Review

MARCH 27, 2023

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 percent between 2022 and 2027. According to the data, the market is forecasted to increase by $2,487.91 The research includes historic market data from 2017 to 2021, using 2022 as the base year.

Compounding 115

Compounding Vaccines 115

Express Pharma

JANUARY 2, 2025

The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 The late-stage T1D pipeline consists of several agents, including Eli Lillys insulin efsitora alfa, which is anticipated to launch in 2027. per cent from $2.2 billion in 2023 to $9.9

Diabetes 105

Diabetes Vaccines Compounding 105

pharmaphorum

FEBRUARY 3, 2022

As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds. There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases.

Compounding 52

Compounding Packaging Biosimilars Vaccines 52

European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Vaccines 98

Vaccines Immunity Immunization Compounding 98

pharmaphorum

JANUARY 16, 2023

Ageing will only compound the challenge: high income country populations are already old, but between 2015 and 2050, the proportion of the world’s population aged over 60 will nearly double, from 12% to 22%, and, by 2050, 80% of older people will be living in low- and middle-income countries. Innovation will power the market.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Compounding Vaccines 98

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Communication Immunity 52